支氣管擴張治療市場：按藥物類別、給藥途徑、分銷管道和地區分類

預計到 2026 年，支氣管擴張治療市場規模將達到 4.492 億美元，到 2033 年將達到 8.979 億美元。預計從 2026 年到 2033 年，該市場將以 10.4% 的複合年成長率成長。

支氣管擴張是指肺部氣道因損傷而擴張或呈囊狀的一種疾病。這會導致肺部粘液難以排放，可能引發頻繁感染疾病。劇烈咳嗽並伴隨膿痰是支氣管擴張的主要症狀。雖然支氣管擴張無法治愈，但可以透過治療進行控制。

支氣管擴張症藥物對於控制支氣管擴張症的症狀和併發症至關重要。支氣管擴張症是一種慢性呼吸系統疾病，其特徵是支氣管擴張。這些藥物旨在緩解慢性咳嗽、痰液過多和反覆呼吸道感染疾病等症狀，同時延緩疾病進展。支氣管擴張症藥物包括支氣管擴張劑、祛痰藥、抗生素和抗發炎藥物。這些藥物的研發為改善患者預後和生活品質開闢了新的可能性。目前，支氣管擴張症的研究正在探索新的治療方法和標靶治療，為更有效的治療和更好的疾病管理帶來了希望。

市場動態

支氣管擴張症盛行率的不斷上升、治療方案的進步以及對個人化醫療日益成長的關注，預計將推動全球支氣管擴張症治療市場在預測期內的成長。此外，有利的法規環境以及市場參與者研發活動的活性化，預計也將促進市場在預測期內的成長。

例如，2022 年 2 月，生物技術公司 Armata Pharmaceuticals, Inc. 宣布，美國食品藥物管理局(FDA) 已批准其最佳化的領先治療候選藥物 AP-PA02的臨床實驗藥物申請 (IND)，以開始針對第二個適應症（囊腫纖維化支氣管擴張症）的臨床試驗。

本研究的主要特點：

• 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究根據以下參數介紹了全球支氣管擴張治療市場主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
• 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 這份「全球支氣管擴張治療市場」報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過利用全球支氣管擴張治療市場分析中使用的各種策略矩陣來簡化決策過程。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• 一致性機會圖（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
    • 支氣管擴張症盛行率增加
    • 對該疾病的認知提高
  • 抑制因子
    • 認知度低和漏診
    • 缺乏具體的治療指南
  • 機會
    • 未滿足的醫療需求
    • 新興市場
• 影響分析
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特的分析
• 併購情景

第4章 支氣管擴張治療市場：依藥物類別分類，2021-2033年

• 抗生素
• 祛痰藥
• 支氣管擴張劑
• 抗發炎藥

第5章 支氣管擴張治療市場：依給藥途徑分類，2021-2033年

• 口服
• 吸入
• 靜脈

第6章 支氣管擴張治療市場：依通路分類，2021-2033年

• 醫院藥房
• 零售藥房
• 網路藥房

第7章 支氣管擴張治療市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • ASEAN
  • 澳洲
  • 其他中東國家
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第8章 競爭情勢

• Bayer
• GlaxoSmithKline
• Boehringer Ingelheim
• Novartis
• AstraZeneca
• Sunovion Pharmaceuticals
• Chiesi Farmaceutici

第9章

• 調查方法
• 關於本公司

Bronchiectasis Drugs Market is estimated to be valued at USD 449.2 Mn in 2026 and is expected to reach USD 897.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 10.4% from 2026 to 2033.

Bronchiectasis is a condition where damage causes the tubes in your lungs (airways) to widen or develop pouches. It makes it hard to clear mucus out of your lungs and can cause frequent infections. Coughing a lot with pus and mucus is the main symptom of bronchiectasis. Bronchiectasis can't be cured but can be managed with treatment.

Bronchiectasis drugs are essential for managing the symptoms and complications of bronchiectasis, a chronic respiratory condition characterized by widening of the bronchial tubes. These drugs aim to alleviate symptoms like chronic cough, excessive mucus production, and recurrent respiratory infections while slowing down disease progression. Bronchiectasis drugs encompass bronchodilators, mucus-clearing agents, antibiotics, and anti-inflammatory medicine. Their development has opened new possibilities for improved patient outcomes and quality of life. Ongoing research in bronchiectasis explores novel therapeutic approaches and targeted medications, offering hope for more effective treatments and better disease management.

Market Dynamics:

The increasing prevalence of bronchiectasis, advancements in treatment options, and increasing focus on personalized medicine are anticipated to drive growth of the global bronchiectasis drugs market over the forecast period. Moreover, a supportive regulatory environment and increased research and developmental activities by market players is expected to drive market growth over the forecast period.

For instance, in February 2022, Armata Pharmaceuticals, Inc., a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared Armata's Investigational New Drug (IND) application to initiate a clinical trial of its optimized lead therapeutic candidate, AP-PA02, in a second indication, non-cystic fibrosis bronchiectasis.

Key features of the study:

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global bronchiectasis drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bayer AG, GlaxoSmithKline, Boehringer Ingelheim, Novartis, AstraZeneca, Sunovion Pharmaceuticals, Chiesi Farmaceutici
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global bronchiectasis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bronchiectasis drugs market

Detailed Segmentation:

• Bronchiectasis drugs market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
• Antibiotics
• Mucolytics
• Bronchodilators
• Anti-inflammatory agents
• Bronchiectasis drugs market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
• Oral
• Inhalation
• Intravenous
• Bronchiectasis drugs market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles:
• Bayer
• GlaxoSmithKline
• Boehringer Ingelheim
• Novartis
• AstraZeneca
• Sunovion Pharmaceuticals
• Chiesi Farmaceutici

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Bronchiectasis Drugs, By Drug Class
  • Market Bronchiectasis Drugs, By Route of Administration
  • Market Bronchiectasis Drugs, By Distribution Channel
  • Market Bronchiectasis Drugs, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
    • Increasing Prevalence of Bronchiectasis
    • Increasing Awareness of the Disease
  • Restraints
    • Limited Awareness and Underdiagnoses
    • Lack of Specific Treatment Guidelines
  • Opportunities
    • Unmet Medical Needs
    • Emerging Markets
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Bronchiectasis Drugs Market , By Drug Class, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Antibiotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Mucolytics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Bronchodilators
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Anti-inflammatory agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

5. Bronchiectasis Drugs Market , By Route of Administration, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
• Inhalation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)

6. Bronchiectasis Drugs Market, By Distribution Channel, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)

7. Bronchiectasis Drugs Market , By Region, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, By Country, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country 2022 -2033
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033,(US$ Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033,(US$ Mn)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033,(US$ Mn)
    • China
    • Japan
    • India
    • South Korea
    • ASEAN
    • Australia
    • Rest of Middle East
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033,(US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033,(US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033,(US$ Mn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Bayer
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Boehringer Ingelheim
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Novartis
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Sunovion Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Chiesi Farmaceutici
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

9. Section

• Research Methodology
• About us